These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 22160089)
1. Immunomodulating drugs in myelodysplastic syndromes. Adès L; Fenaux P Hematology Am Soc Hematol Educ Program; 2011; 2011():556-60. PubMed ID: 22160089 [TBL] [Abstract][Full Text] [Related]
2. The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: a clinical practice guideline. Leitch HA; Buckstein R; Shamy A; Storring JM Crit Rev Oncol Hematol; 2013 Feb; 85(2):162-92. PubMed ID: 22901762 [TBL] [Abstract][Full Text] [Related]
3. Lenalidomide for treatment of myelodysplastic syndromes. Komrokji RS; List AF Curr Pharm Des; 2012; 18(22):3198-203. PubMed ID: 22571699 [TBL] [Abstract][Full Text] [Related]
4. Role of lenalidomide in the treatment of myelodysplastic syndromes. Komrokji RS; List AF Semin Oncol; 2011 Oct; 38(5):648-57. PubMed ID: 21943671 [TBL] [Abstract][Full Text] [Related]
5. Lenalidomide treatment induced the normalization of marker protein levels in blood plasma of patients with 5q-myelodysplastic syndrome. Messingerová L; Jonášová A; Barančik M; Poleková L; Šereš M; Gibalová L; Breier A; Sulová Z Gen Physiol Biophys; 2015 Oct; 34(4):399-406. PubMed ID: 26001289 [TBL] [Abstract][Full Text] [Related]
6. Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes. List A Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S302-4. PubMed ID: 19778857 [TBL] [Abstract][Full Text] [Related]
7. Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications. Stahl M; Zeidan AM Cancer; 2017 May; 123(10):1703-1713. PubMed ID: 28192601 [TBL] [Abstract][Full Text] [Related]
9. Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency. Arcioni F; Roncadori A; Di Battista V; Tura S; Covezzoli A; Cundari S; Mecucci C; Eur J Haematol; 2018 Jul; 101(1):78-85. PubMed ID: 29569278 [TBL] [Abstract][Full Text] [Related]
10. Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide. Gaballa MR; Besa EC Ann Hematol; 2014 May; 93(5):723-33. PubMed ID: 24627193 [TBL] [Abstract][Full Text] [Related]
11. Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy. Prebet T; Toma A; Cluzeau T; Sekeres MA; Vey N; Park S; Al Ali N; Sugrue MM; Komrokji R; Fenaux P; Gore SD Oncotarget; 2017 Jun; 8(23):37866-37874. PubMed ID: 28184031 [TBL] [Abstract][Full Text] [Related]
12. Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q). Butrym A; Lech-Maranda E; Patkowska E; Kumiega B; Bieniaszewska M; Mital A; Madry K; Torosian T; Wichary R; Rybka J; Warzocha K; Mazur G BMC Cancer; 2015 Jul; 15():508. PubMed ID: 26152663 [TBL] [Abstract][Full Text] [Related]
13. A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes. Fang J; Liu X; Bolanos L; Barker B; Rigolino C; Cortelezzi A; Oliva EN; Cuzzola M; Grimes HL; Fontanillo C; Komurov K; MacBeth K; Starczynowski DT Nat Med; 2016 Jul; 22(7):727-34. PubMed ID: 27294874 [TBL] [Abstract][Full Text] [Related]
14. Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria. Aschauer G; Greil R; Linkesch W; Nösslinger T; Stauder R; Burgstaller S; Fiegl M; Fridrik M; Girschikofsky M; Keil F; Petzer A Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e143-9. PubMed ID: 26422252 [TBL] [Abstract][Full Text] [Related]
16. Lenalidomide performance in the real world: patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes. Zeidan AM; Gore SD; McNally DL; Baer MR; Hendrick F; Mahmoud D; Davidoff AJ Cancer; 2013 Nov; 119(21):3870-8. PubMed ID: 23922173 [TBL] [Abstract][Full Text] [Related]
17. Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more? Komrokji RS; Lancet JE; List AF Curr Hematol Malig Rep; 2010 Jan; 5(1):9-14. PubMed ID: 20425391 [TBL] [Abstract][Full Text] [Related]
18. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents. Sibon D; Cannas G; Baracco F; Prebet T; Vey N; Banos A; Besson C; Corm S; Blanc M; Slama B; Perrier H; Fenaux P; Wattel E; Br J Haematol; 2012 Mar; 156(5):619-25. PubMed ID: 22211483 [TBL] [Abstract][Full Text] [Related]
19. Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome. Maier SK; Hammond JM Ann Pharmacother; 2006 Feb; 40(2):286-9. PubMed ID: 16403850 [TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory drugs in the treatment of myelodysplastic syndromes. Ortega J; List A Curr Opin Oncol; 2007 Nov; 19(6):656-9. PubMed ID: 17906467 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]